**
In a revelation that has raised eyebrows across the regulatory landscape, internal records have surfaced detailing a meeting between top officials at the Environmental Protection Agency (EPA) and Bayer’s CEO, Bill Anderson. The discussions, which took place on June 17, 2025, focused on litigation surrounding Bayer’s glyphosate-based herbicides, including the widely used Roundup. This encounter occurred just months before the Trump administration took significant steps to bolster Bayer’s position in an ongoing legal battle over alleged cancer risks associated with its products.
High-Stakes Conversations
Government records indicate that the meeting involved key EPA figures, including Lee Zeldin, the agency’s administrator, and Nancy Beck, who previously held a prominent role at the American Chemistry Council. The agenda reportedly included “supreme court action” and an update on Bayer’s legal strategies to mitigate the financial toll stemming from lawsuits filed by thousands claiming to have developed cancer due to glyphosate exposure.
Bayer’s strategic approach involves arguing that if the EPA does not mandate a cancer warning on its glyphosate products, the company cannot be held liable for any potential health risks. While some courts have sided with Bayer, many others have rejected this argument, and the Biden administration’s solicitor general has also expressed opposition to Bayer’s claims.
Unusual Support from the Administration
Following the June meeting, the Trump administration’s support for Bayer appeared to intensify. On December 1, 2025, the administration’s solicitor general, D. John Sauer, urged the Supreme Court to hear Bayer’s case, a request that was subsequently granted, scheduling a hearing for April 27, 2026. Furthermore, on February 18, 2026, the White House invoked the Defense Production Act to safeguard the production of glyphosate products, effectively providing immunity to manufacturers like Bayer.
Bayer has defended the meeting as a standard aspect of the regulatory process, asserting transparency regarding its litigation stance. However, critics, including Nathan Donley from the Center for Biological Diversity, have voiced concerns that such meetings illustrate an alarming trend of corporate influence over regulatory bodies, potentially at the expense of public health.
Public Outcry and Legal Concerns
The implications of this meeting extend beyond corporate interests, as advocacy groups and legal experts express alarm over the apparent prioritisation of Bayer’s financial concerns over the health of consumers. Whitney Di Bona, a consumer safety advocate, highlighted the troubling nature of a major pesticide company’s CEO having direct access to EPA officials to discuss limiting liability, questioning whether the same opportunities were afforded to those adversely affected by glyphosate.
Naomi Oreskes, a Harvard professor who studies corporate influence in regulatory practices, noted that the meeting reflects a broader pattern where industry leaders have preferential access to government officials, overshadowing the voices of ordinary citizens seeking accountability and protection from harmful substances.
Zen Honeycutt, founder of Moms Across America, echoed these sentiments, stating that the influence of chemical companies on regulatory agencies is a long-standing issue. Despite her organisation’s attempts to engage with the EPA on pesticide regulation, she has seen little progress in terms of meaningful action.
Why it Matters
The implications of this meeting and the subsequent actions taken by the Trump administration extend far beyond Bayer’s litigation woes. This situation exemplifies a concerning dynamic where influential corporations can exert significant pressure on regulatory agencies, potentially compromising public health for corporate profit. The ongoing legal battles over glyphosate not only raise questions about the safety of widely used products but also underscore the urgent need for transparency and accountability in regulatory processes. As more details emerge, the public must remain vigilant in demanding that health considerations take precedence over corporate interests in shaping policy and regulation.
